Top Things to Know: Surviving Pediatric Cardiogenic Shock: Clinical Approach, Improving Outcomes, & Future Directions
Updated: August 06, 2026
Prepared by Kriti Puri, MBBS, Aamir Jeewa MBBCh
- This scientific statement defines and frames pediatric cardiogenic shock (CS), a condition associated with up to 25% mortality, as well as substantial morbidity including mechanical ventilation, cardiac arrest, renal replacement therapy, and liver failure. Progress has been limited by inconsistent definitions and practice variability.
- The statement proposes a standardized definition of pediatric CS, aligned with adult frameworks: known or suspected cardiac dysfunction resulting in clinical and/or biochemical evidence of tissue hypoperfusion, indicated by ≥1 of the following: cool extremities, lactate >2 mmol/L, abnormal hepatic or renal function, irritability, or altered mentation.
- A staged severity classification (Stages A–E) is introduced to standardize communication and define trajectory, ranging from patients at risk (Stage A), to early hemodynamic compromise without hypoperfusion (Stage B), to classic hypoperfused CS (Stage C), deteriorating CS with hypoperfusion despite initial therapy (Stage D), and shock in extremis requiring resuscitation (Stage E).
- In children with acute decompensated heart failure and suspected CS, rapid assessment of congestion and hypoperfusion (using examination, laboratory testing, and imaging) guides targeted decongestion, inotrope use, and reduction of myocardial oxygen demand.
- Because many patients worsen within the first 24 hours after presentation, serial reassessment of perfusion and oxygen delivery (clinical exam and hemodynamics, lactate, central venous oxygen saturation/near infrared spectroscopy, oxygen extraction) is essential to guide escalation and clarify trajectory.
- Management integrates evaluation of oxygen delivery and end-organ function to titrate inotropes/inodilators, volume assessment and central venous pressure monitoring to guide decongestion, and use of positive pressure ventilation to reduce afterload, improve oxygenation, and decrease oxygen consumption.
- If medical therapy fails to restore perfusion and preserve end-organ function, temporary mechanical circulatory support (MCS) may be required. Pediatric device selection depends on patient size and anatomy, urgency, pulmonary involvement, underlying etiology, anticipated course, and risk of biventricular failure.
- Decisions about triage, choosing medical versus MCS therapy, and determining the timing of escalation rely on multiple factors. These include the shock severity stage, the extent of hemodynamic and end‑organ compromise, the underlying clinical phenotype and chronicity, and patient‑specific risk modifiers such as age, history of cardiac arrest, congenital heart disease, and other comorbidities.
- Socioeconomic determinants are linked to worse pediatric heart failure outcomes, but their specific impact in pediatric CS remains insufficiently characterized.
- Future priorities include broad adoption of consensus definitions and staging, deep phenotypic characterization, validation of biomarkers for risk stratification, and development of integrated clinical algorithms to improve outcomes.
Citation
Puri K, Allen K, Jentzer J, Soderstrom R, Lorts A, Schumacher K, Barnes S, Greene CL, Jeewa A; on behalf of the American Heart Association’s Young Hearts Pediatric and Congenital Critical Care Cardiology Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young. Surviving pediatric cardiogenic shock: clinical approach, improving outcomes, and future directions: a scientific statement from the American Heart Association. Circulation. Published online August 6, 2026. doi: 10.1161/CIR.0000000000001461